Mark Zorbas

538 total citations
23 papers, 446 citations indexed

About

Mark Zorbas is a scholar working on Oncology, Molecular Biology and Physiology. According to data from OpenAlex, Mark Zorbas has authored 23 papers receiving a total of 446 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Oncology, 6 papers in Molecular Biology and 6 papers in Physiology. Recurrent topics in Mark Zorbas's work include Pain Mechanisms and Treatments (6 papers), HIV/AIDS drug development and treatment (5 papers) and HIV Research and Treatment (3 papers). Mark Zorbas is often cited by papers focused on Pain Mechanisms and Treatments (6 papers), HIV/AIDS drug development and treatment (5 papers) and HIV Research and Treatment (3 papers). Mark Zorbas collaborates with scholars based in United States, Japan and Denmark. Mark Zorbas's co-authors include Lynn C. Yeoman, David L. Shelton, Stephanie Webber, Gary E. Gallick, Susan Hurst, Bhasker V. Shetty, Matilde Olivé, Amy K. Patick, Bradley M. Kerr and Xinglin Wu and has published in prestigious journals such as Neuroscience, Antimicrobial Agents and Chemotherapy and Annals of the Rheumatic Diseases.

In The Last Decade

Mark Zorbas

23 papers receiving 436 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Mark Zorbas United States 12 116 113 94 71 59 23 446
Simona Signorini Italy 13 51 0.4× 86 0.8× 41 0.4× 177 2.5× 32 0.5× 24 504
Margareta Klein Sweden 7 98 0.8× 142 1.3× 67 0.7× 52 0.7× 17 0.3× 8 767
Giuseppe Biondi Italy 7 110 0.9× 68 0.6× 19 0.2× 38 0.5× 18 0.3× 7 345
Bonnie Pobiner United States 11 22 0.2× 223 2.0× 22 0.2× 54 0.8× 57 1.0× 18 452
Federica Barchiesi Switzerland 12 71 0.6× 162 1.4× 22 0.2× 24 0.3× 26 0.4× 13 557
Lidan Xu China 15 73 0.6× 234 2.1× 17 0.2× 33 0.5× 12 0.2× 48 477
Folefac Aminkeng Singapore 14 194 1.7× 202 1.8× 35 0.4× 20 0.3× 104 1.8× 26 689
Isabel Huber‐Ruano Spain 11 110 0.9× 166 1.5× 70 0.7× 43 0.6× 5 0.1× 15 401
B. Baudin France 12 29 0.3× 137 1.2× 32 0.3× 89 1.3× 26 0.4× 27 454
Nina Lahdenpohja Finland 9 83 0.7× 106 0.9× 27 0.3× 70 1.0× 8 0.1× 9 476

Countries citing papers authored by Mark Zorbas

Since Specialization
Citations

This map shows the geographic impact of Mark Zorbas's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark Zorbas with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark Zorbas more than expected).

Fields of papers citing papers by Mark Zorbas

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark Zorbas. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark Zorbas. The network helps show where Mark Zorbas may publish in the future.

Co-authorship network of co-authors of Mark Zorbas

This figure shows the co-authorship network connecting the top 25 collaborators of Mark Zorbas. A scholar is included among the top collaborators of Mark Zorbas based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mark Zorbas. Mark Zorbas is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Gropp, Kathryn E., Cathy S. Carlson, Mark G. Evans, et al.. (2018). Effects of Monoclonal Antibodies against Nerve Growth Factor on Healthy Bone and Joint Tissues in Mice, Rats, and Monkeys: Histopathologic, Biomarker, and Microcomputed Tomographic Assessments. Toxicologic Pathology. 46(4). 408–420. 9 indexed citations
3.
4.
Marcek, John, Carlin V. Okerberg, Chang‐Ning Liu, et al.. (2016). Anti-NGF monoclonal antibody muMab 911 does not deplete neurons in the superior cervical ganglia of young or old adult rats. Journal of Chemical Neuroanatomy. 76(Pt B). 133–141. 5 indexed citations
5.
LaBranche, Timothy P., Alison M. Bendele, Kathryn E. Gropp, et al.. (2016). Nerve growth factor inhibition with tanezumab influences weight-bearing and subsequent cartilage damage in the rat medial meniscal tear model. Annals of the Rheumatic Diseases. 76(1). 295–302. 44 indexed citations
6.
Bowman, Christopher, Mark G. Evans, Satoru Oneda, et al.. (2014). Developmental toxicity assessment of tanezumab, an anti-nerve growth factor monoclonal antibody, in cynomolgus monkeys (Macaca fascicularis). Reproductive Toxicology. 53. 105–118. 12 indexed citations
7.
8.
Lankford, Karen L., Edgardo J. Arroyo, Chang‐Ning Liu, et al.. (2013). Sciatic nerve regeneration is not inhibited by anti-NGF antibody treatment in the adult rat. Neuroscience. 241. 157–169. 8 indexed citations
9.
Zorbas, Mark, Susan Hurst, David L. Shelton, et al.. (2010). A multiple-dose toxicity study of tanezumab in cynomolgus monkeys. Regulatory Toxicology and Pharmacology. 59(2). 334–342. 24 indexed citations
10.
Burns‐Naas, Leigh Ann, et al.. (2005). Lack of Respiratory and Contact Sensitizing Potential of the Intranasal Antiviral Drug Candidate Rupintrivir (AG7088): A Weight-of-the-Evidence Evaluation. Journal of Immunotoxicology. 2(3). 123–139. 2 indexed citations
11.
Burns‐Naas, Leigh Ann, et al.. (2003). Absence of embryo-fetal toxicity in rats or rabbits following oral dosing with nelfinavir. Regulatory Toxicology and Pharmacology. 38(3). 291–303. 3 indexed citations
12.
Burns‐Naas, Leigh Ann, et al.. (2003). Absence of reproductive and developmental toxicity in rats following oral dosing with nelfinavir. Regulatory Toxicology and Pharmacology. 38(3). 304–316. 3 indexed citations
13.
Wu, Xinglin, Amy K. Patick, Bradley M. Kerr, et al.. (2001). Circulating Metabolites of the Human Immunodeficiency Virus Protease Inhibitor Nelfinavir in Humans: Structural Identification, Levels in Plasma, and Antiviral Activities. Antimicrobial Agents and Chemotherapy. 45(8). 2405–2405. 1 indexed citations
14.
Wu, Xinglin, Amy K. Patick, Bradley M. Kerr, et al.. (2001). Circulating Metabolites of the Human Immunodeficiency Virus Protease Inhibitor Nelfinavir in Humans: Structural Identification, Levels in Plasma, and Antiviral Activities. Antimicrobial Agents and Chemotherapy. 45(4). 1086–1093. 107 indexed citations
15.
McLeod, Howard L., J Cassidy, David G. Priest, et al.. (2000). Pharmacokinetic and pharmacodynamic evaluation of the glycinamide ribonucleotide formyltransferase inhibitor AG2034.. PubMed. 6(7). 2677–84. 34 indexed citations
16.
Yeoman, Lynn C., et al.. (1996). Transferrin and insulin enhance human colon tumor cell growth by differentiation class specific mechanisms.. PubMed. 8(7-8). 273–9. 9 indexed citations
17.
18.
Zorbas, Mark & Lynn C. Yeoman. (1993). Growth Control in a Human Colon Carcinoma Cell Line Mediated by Cell-Associated Transforming Growth Factor-α (TGFα). Experimental Cell Research. 206(1). 49–57. 11 indexed citations
19.
Gross, Mitchell E., Mark Zorbas, R. García, et al.. (1991). Cellular growth response to epidermal growth factor in colon carcinoma cells with an amplified epidermal growth factor receptor derived from a familial adenomatous polyposis patient.. PubMed. 51(5). 1452–9. 70 indexed citations
20.
Zorbas, Mark, et al.. (1989). The pharmacokinetics of [3H]1-[1-(2-thienyl)cyclohexyl]piperidine (TCP) in Sprague-Dawley rats.. Drug Metabolism and Disposition. 17(6). 641–645. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Simona Signorini Breakdown of academic impact, for papers by Margareta Klein Breakdown of academic impact, for papers by Giuseppe Biondi Breakdown of academic impact, for papers by Bonnie Pobiner Breakdown of academic impact, for papers by Federica Barchiesi Breakdown of academic impact, for papers by Lidan Xu Breakdown of academic impact, for papers by Folefac Aminkeng Breakdown of academic impact, for papers by Isabel Huber‐Ruano Breakdown of academic impact, for papers by B. Baudin Breakdown of academic impact, for papers by Nina Lahdenpohja
Rankless by CCL
2026